Serum RANTES, MIP-1α, and MCP-1 levels in Behçet’s disease

Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behçet’s disease

“…Changes in cytokine and chemokine levels in patients with BD were extensively investigated by different research groups using various methods, the results of which are summarized in Table 1 8,10–21 . Although the Th1‐type immune response was supported by the investigation of serum cytokine levels and cytokine production by peripheral blood lymphocytes, 10 divergent cytokine production profiles of peripheral blood mononuclear cells from patients with BD or BD sera were also reported 18 .…”

Promoter –2518 single nucleotide polymorphism of monocyte chemoattractant protein-1 is associated with clinical severity in Behçet’s disease

“…In addition, MCP levels in the blood of BD patients were significantly higher than in either healthy controls or disease controls including thrombophilic disorders [8][9][10]. However, in the literature, there are contrasting findings showing no significant differences in serum MCP-1 levels between BD and either familial Mediterranean fever or healthy controls [11]. In two clinical studies, some relationship between polymorphism at promoter -2518 locus of the MCP-1 gene and a few clinical symptoms of BD, including ocular or gastrointestinal involvement, was demonstrated [10,12].…”

“…Some investigations have demonstrated that increased expression of MCP-1 was detected in BD patients [8][9][10]. In contrast, Ozer et al [11] showed no significant increase in MCP-1 levels in BD compared to healthy and disease controls. Another study conducted in eight BD patients with active mucocutaneous lesions reported that serum MCP-1 levels were unchanged before and after treatment with azithromycin [19].…”

Etiology, Immunopathogenesis and Biomarkers in Behçet’s disease

“…In regard to β-chemokines, Ozer et al found significantly elevated levels of MCP1/CCL2, MIP1α/CCL3, and RANTES/CCL5 in active BD serum than in HC [175] in BD patients compared to HC [178,179]. In CSF of neuro-BD patients, Saruhan-Direskeneli et al and Miyagishi et al both demonstrated significantly higher levels of MIP1α/CCL3 compared to NIN [168,180].…”